A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1005 | Th1002 | Cetuximab | Heavy chain:QVQLKQSG Full view | 243 | IIIc | Cancer | Erbitux | ImClone Systems Inc | Sterile, clear, colorless liquid of pH 7.0-7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates | Intravenous infusion | Antineoplastic Agents | Epidermal growth factor receptor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1025 | Th1004 | Denileukin diftitox | MGADDVVDSSKSFVMENFSS Full view | 255 | IIb | Cancer | Ontak | Seragen Inc | Sterile, white, preservative-free, lyophilized powder. | Intravenous(IV) administration | Antineoplastic Agents | Interleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Cytokine receptor common subunit gamma |
| 1028 | Th1005 | Etanercept | LPAQVAFTPYAPEPGSTCRL Full view | 255 | IIa | Immunological | Enbrel | Immunex Corp | Lyophilized powder. | Subcutaneous injection | Immunosuppressive Agents | Tumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
| 1029 | Th1005 | Etanercept | LPAQVAFTPYAPEPGSTCRL Full view | 255 | IIa | Immunological | Enbrel Sureclick | N.A. | Solution | Subcutaneous injection | Immunosuppressive Agents | Tumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
| 1038 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Eligard | Atrix Labs/QLT In | Suspension | Subcutaneous Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1039 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Enantone | Takeda | Solution | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1040 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Leuplin | Takeda | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1041 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | LeuProMaxx | Baxter/Teva | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1042 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Leupromer | N.A. | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1043 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Lupron | Abbott/TAP Pharmaceuticals | N.A. | Injection | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1044 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Lutrate | N.A. | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1045 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Memryte | Curaxis | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1046 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Prostap 3 | Takeda UK Limited | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1047 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Prostap SR | Takeda UK Limited | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1048 | Th1007 | Leuprolide | PHWSYLLR Full view | 8 | IIa | Cancer | Viadur | Bayer AG | N.A. | N.A. | Antineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | Gonadotropin-releasing hormone receptor |
| 1049 | Th1008 | Peginterferon alfa-2a | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | Pegasys | Hoffman-La Roche Inc | Sterile, preservative-free, colorless to light yellow injectable solution | Subcutaneous Injection | Immunosuppressive Agents | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1055 | Th1009 | Alteplase | SYQVICRDEKTQMIYQQHQS Full view | 255 | Ib | Hematological,Metabolic | Activase | Genentech Inc | Sterile, white to off-white, lyophilized powder | Intravenous | Thrombolytic Agents | Plasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
| 1059 | Th1010 | Interferon alfa-n1 | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Infectious /Immunological | Wellferon | GlaxoSmithKline | Solution | Injection | Antiviral Agents, Immunologic factors, Immunosuppressiv agents | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1064 | Th1011 | Darbepoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Aranesp | Amgen Inc | Sterile, colorless, preservative-free solution containing polysorbate | Intravenousor Subcutaneous administration | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1067 | Th1012 | Reteplase | SYQGNSDCYFGNGSAYRGTH Full view | 255 | Ib | Hematological,Metabolic | Retavase | Centocor | Sterile, white, lyophilized powder | Intravenous Injection | Fibrinolytic Agents, Thrombolytic agents | Plasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
| 1071 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Binocrit | Sandoz | Clear colourless solution | Subcutaneous and Intravenous infusion | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1072 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Epocept | Lupin pharma | N.A. | Injection | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1073 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Epofit | Intas pharma | N.A. | N.A. | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1074 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Epogen | Amgen Inc. | Sterile, colorless liquid | Subcutaneous Injection | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1075 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Epogin | Chugai | N.A. | Subcutaneous or by Intravenous. | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1076 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Eprex | Janssen-Cilag. Ortho Biologics LLC | Solution | Subcutaneous and Intravenous infusion | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1077 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Nanokine | Nanogen Pharmaceutical biotechnology, Vietnam) | Sterile, white, lyophilized powder. The reconstituted preparation with 1 ml solvent (containing 0.9% benzyl alcohol) results in a clear, colorless solution. | Injection | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1078 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Procrit | Ortho Biotech | Sterile, colorless liquid in an isotonic sodium chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate buffered solution | Intravenous(IV) or Subcutaneous (SC) administration. | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1098 | Th1014 | Salmon Calcitonin | CSNLSTCVLGKLSQELHKLQ Full view | 32 | Ib | Osteological | Calcimar | N.A. | Solution | Subcutaneous or Intramuscular Injection | Bone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | Calcitonin receptor |
| 1099 | Th1014 | Salmon Calcitonin | CSNLSTCVLGKLSQELHKLQ Full view | 32 | Ib | Osteological | Fortical | N.A. | Nasal spray | Intranasal use | Bone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | Calcitonin receptor |
| 1100 | Th1014 | Salmon Calcitonin | CSNLSTCVLGKLSQELHKLQ Full view | 32 | Ib | Osteological | Miacalcin | Novartis | Solution | Subcutaneous or Intramuscular Injection | Bone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | Calcitonin receptor |
| 1110 | Th1015 | Interferon alfa-n3 | Alpha-2A:CDLPQTHSLG< Full view | 235 | Ib | Immunological | Alferon | Interferon Sciences Inc. | Solution | Injection | Immunosuppressive Agents | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1111 | Th1015 | Interferon alfa-n3 | Alpha-2A:CDLPQTHSLG< Full view | 235 | Ib | Immunological | Alferon LDO | N.A. | N.A. | N.A. | Immunosuppressive Agents | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1112 | Th1015 | Interferon alfa-n3 | Alpha-2A:CDLPQTHSLG< Full view | 235 | Ib | Immunological | Alferon N Injection | N.A. | N.A. | N.A. | Immunosuppressive Agents | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1117 | Th1016 | Pegfilgrastim | MTPLGPASSLPQSFLLKCLE Full view | 175 | Ib | Immunological | Neulasta | Amgen Inc. | Solution | Subcutaneous injection | Immunosuppressive Agents, Anti-neutropenic agents | Granulocyte colony-stimulating factor receptor,Neutrophil elastase |
| 1120 | Th1017 | Sargramostim | APARSPSPSTQPWEHVNAIQ Full view | 127 | Ib | Immunological | Leucomax | Novartis | Solution | Subcutaneous and Intravenous infusion | Immunosuppressive Agents | Granulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
| 1121 | Th1017 | Sargramostim | APARSPSPSTQPWEHVNAIQ Full view | 127 | Ib | Immunological | Leukine | Berlex Laboratories Inc | Sterile, preserved (1.1% benzyl alcohol), injectable solution (500 mcg/mL) and also as sterile, white, preservative free lyophilized powder (250 mcg) that requires reconstitution with 1 mL sterile water for Injection | Subcutaneous Injection (SC) or Intravenous infusion (IV) | Immunosuppressive Agents | Granulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
| 1129 | Th1018 | Secretin | HSDGTFTSELSRLRDSARLQ Full view | 27 | IV | Hormonal disorders | SecreFlo | Repligen Corp | Lyophilized white powder | Intravenous infusion | Diagnostic Agents | Secretin receptor |
| 1130 | Th1018 | Secretin | HSDGTFTSELSRLRDSARLQ Full view | 27 | IV | Hormonal disorders | Secremax | Repligen Corp | Solution | Intravenous | Diagnostic Agents | Secretin receptor |
| 1135 | Th1019 | Peginterferon alfa-2b | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | PEG-Intron | Schering Corp | Powder | Subcutaneous injection | Immunosuppressive Agents | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1136 | Th1019 | Peginterferon alfa-2b | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | Unitron PEG | N.A. | Lyophilized powder | Subcutaneous injection | Immunosuppressive Agents | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1145 | Th1021 | Thyrotropin Alfa | Alpha chain:APDVQDC< Full view | 204 | IV | Cancer | Thyrogen | Genzyme Inc | Lyophilized powder | Intramuscular preferably the buttocks | Diagnostic Agents | Thyrotropin receptor |
| 1148 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Advate | N.A. | Powder form | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1149 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Alphanate | N.A. | Lyophilized powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1150 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Bioclate | Baxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc. | Sterile, nonpyrogenic, off-white to faint yellow, lyophilized powder | Intravenous infusion | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1151 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Helixate FS | N.A. | Sterile, stable, purified, nonpyrogenic, dried concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1152 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hemofil M | N.A. | Dry concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1153 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hyate:C | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1154 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Koate-HP | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
| 1155 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Kogenate FS | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |